If FDA approves Bayer AG's entire dose titration scheme for Adempas riociguat, the agency will be departing from its past decisions on PAH drugs, which have been determined by significant improvements on six-minute walk distance, not by surrogate cardiopulmonary markers.

The agency's Cardiovascular and Renal Drugs Advisory Committee laid the groundwork last week.